# William Dai

> William Dai is a Series A investor at Shangbay Capital backing Health Care and Medical. See 18 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Shangbay Capital](https://shizune.co/investors/profile/shangbay-capital)
- Location: Palo Alto, United States
- Total investments: 18
- Last investment: Jul 2026
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/william-dai-65402419/

William Dai is a Series A investor at Shangbay Capital in Palo Alto focused on Health Care and Medical. William Dai serves as the Founding Managing Partner at ShangBay Capital.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 11 | 61% |
| Medical | 8 | 44% |
| Medical Device | 8 | 44% |
| Biotechnology | 4 | 22% |
| Neuroscience | 3 | 17% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 33% |
| Series B | 4 | 22% |
| Seed | 2 | 11% |
| Series C | 2 | 11% |
| Funding Round | 2 | 11% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 11 | 61% |
| Canada | 1 | 6% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Sound Health | Sound Health uses acoustic resonance to provide nasal relief. Its current product is an app that scans the face to map the bone structure and then a headband that plays music at personalized frequencies for 10 minutes. The headband is off the shelf and the sound levels are akin to wearing earpods. It envisions the headband to be over-the-counter(OTC) so it’s easily accessible to patients, whether prescribed by doctors or not. | $12.3M | Series A | Jul 30, 2026 |  |
| Fluid Biomed | Fluid Biotech is a Calgary based company that aims to develop the next generation of stents to improve patient well-being and realise better health and quality of life through innovation. | $27M | Series A | Dec 16, 2024 |  |
| Avation Medical | Avation Medical is pioneering new platforms for wearable nerve stimulation systems. They believe empowering patients to be in control of their therapies will allow for more personalized and custom care. That's why at Avation Medical, they are re‑imagining neuromodulation by developing patient‑centric solutions based on powerful, proven, smarttechnologies.Avation Medical transforms the neuromodulation market to elevate care for patients with chronic conditions. | $22M | Series C | Feb 01, 2024 |  |
| Laplace Interventional | Laplace developing Transcatheter Tricuspid Valve Technology to offer an increase in life expectancy and an improvement to the quality of life to worldwide patients with tricuspid regurgitation. | $12.9M | Series B | Jul 24, 2023 |  |
| Luminopia | Luminopia develops a new class of treatments for significant neuro-visual disorders. The company is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. As an Innovation Partner of Boston Children’s Hospital, the company is developing its lead product, Luminopia One, totreat amblyopia, the cause of vision loss among children. | $16M | Series A | Jun 27, 2023 |  |
| SetPoint Medical | SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $80M |  | Jan 19, 2023 |  |
| SetPoint Medical | SetPoint Medical is a company that developed a device-based therapeutic approach for treating rheumatoid arthritis. The company's product, the SetPoint System, is a small, wireless implantable device that stimulates the vagus nerve to reduce inflammation. The therapy is an approach for adults with active rheumatoid arthritis who have notresponded to other treatments. | $80M | Series C | Jan 19, 2023 |  |
| Luminopia | Luminopia develops a new class of treatments for significant neuro-visual disorders. The company is committed to creating digital therapeutics that are both rigorously evaluated for FDA approval and genuinely engaging for patients. As an Innovation Partner of Boston Children’s Hospital, the company is developing its lead product, Luminopia One, totreat amblyopia, the cause of vision loss among children. | $5.7M | Seed | Oct 19, 2022 |  |
| Laplace Interventional | Laplace developing Transcatheter Tricuspid Valve Technology to offer an increase in life expectancy and an improvement to the quality of life to worldwide patients with tricuspid regurgitation. | $7.9M | Series A | Sep 01, 2021 |  |
| Fluid Biomed | Fluid Biotech is a Calgary based company that aims to develop the next generation of stents to improve patient well-being and realise better health and quality of life through innovation. | $4.7M | Seed | Aug 11, 2021 |  |

10 of 18 investments shown.

## Co-investors
- [Action Potential Venture Capital](https://shizune.co/investors/profile/action-potential-venture-capital) — VC Fund, 4 deals together
- [Catalio Capital Management](https://shizune.co/investors/profile/catalio-capital-management) — VC Fund, 4 deals together
- [Morgenthaler Ventures](https://shizune.co/investors/profile/morgenthaler-ventures) — VC Fund, 4 deals together
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund, 4 deals together
- [Richard King Mellon Foundation](https://shizune.co/investors/profile/richard-king-mellon-foundation) — VC Fund, 4 deals together
- [SVE Capital](https://shizune.co/investors/profile/sve-capital) — VC Fund, 4 deals together

## About Shangbay Capital

VC Fund · Palo Alto, United States

Best-in-class investments mainly in the U.S. medical devices technology, as well as biotech, and mobile healthcare sectors through early sta

2 contacts available at Shangbay Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Erik Engelson | Venture Partner | https://shizune.co/investors/profile/erik-engelson |
| William Dai | Founding Managing Partner | https://shizune.co/investors/profile/dai-william |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does William Dai invest in?

William Dai invests primarily in Health Care, Medical and Medical Device startups, most often at Series A and Series B stage. Most of the 18 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did William Dai last invest?

The most recent investment recorded for William Dai closed in Jul 2026. Shizune tracks 18 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co